Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy
2008
Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy
Sample size: 639
publication
Evidence: moderate
Author Information
Author(s): Kume Shinji, Uzu Takashi, Isshiki Keiji, Koya Daisuke
Primary Institution: Shiga University of Medical Science
Hypothesis
PPAR agonists might prevent the progression of diabetic nephropathy.
Conclusion
PPAR agonists have a beneficial effect on diabetic nephropathy compared to other antidiabetic agents.
Supporting Evidence
- PPAR agonists improve dyslipidemia and insulin resistance.
- Clinical trials confirm the renoprotective action of PPARγ.
- PPARγ agonists are effective in preventing type 2 diabetic nephropathy.
Takeaway
This study talks about how certain medicines can help people with diabetes avoid kidney problems.
Methodology
The review summarizes data from clinical and experimental studies regarding the relationship between PPARs and diabetic nephropathy.
Limitations
The review does not provide extensive clinical data on PPARβ/δ.
Participant Demographics
Patients with type 2 diabetes.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website